
Opinion|Videos|October 21, 2024
Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.
Advertisement
Video Player is loading.
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves subcutaneous pembrolizumab
2
FDA grants 510(k) clearance to new edition of Focal One robotic HIFU
3
Kim Nguyen Chi, MD, highlights patient-reported outcome data from AMPLITUDE
4
Microultrasonography positioned as alternative to MRI for image-guided prostate biopsy
5














